CN Patent

CN103458919A — 在2型糖尿病患者中预防低血糖症

Assigned to Sanofi Aventis Deutschland GmbH · Expires 2013-12-18 · 12y expired

What this patent protects

用于预防在2型糖尿病中的低血糖症的方法，包括向有该需要的受试者施用(a)desPro 36 毒蜥外泌肽-4(1-39)-Lys 6 -NH 2 或/和其药学可接受的盐，以及(b)二甲双胍或/和其药学可接受的盐。

USPTO Abstract

用于预防在2型糖尿病中的低血糖症的方法，包括向有该需要的受试者施用(a)desPro 36 毒蜥外泌肽-4(1-39)-Lys 6 -NH 2 或/和其药学可接受的盐，以及(b)二甲双胍或/和其药学可接受的盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN103458919A
Jurisdiction
CN
Classification
—
Expires
2013-12-18
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi Aventis Deutschland GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.